Navigation Links
Solos Endoscopy, Inc. Applauds American College of Surgeons Review of Advanced Breast Cancer Detection at 94th Annual Clinical Congress
Date:10/23/2008

BOSTON, Oct. 23 /PRNewswire-FirstCall/ -- Solos Endoscopy, Inc. (Pink Sheets: SNDY) is pleased to announce that advanced breast cancer detection through the use of mammary ductoscopy was a featured topic and reviewed in panel discussions at the 94th Annual American College of Surgeons Clinical Congress in San Francisco, CA. The panel discussed the understanding of the ductal lobular anatomy of the breast and ductal pathologic entities. The Company's current mission is to continue to increase use of its Mammo View(TM) ductoscopy product line in hospitals and breast clinics around the country.

Solos Endoscopy's Mammo View(TM) product line employs advanced micro endoscopes and optical technology to give physicians sharp, clear images of the mammary ducts where the majority of breast cancers arise. The Mammo View(TM) system contains versatile and customizable medical equipment that can support multiple procedures including biopsies, lumpectomies, and other intraductal procedures. The Mammo View(TM) has the potential to help the early diagnosis of more than 1 million cases of breast cancer discovered each year throughout the world.

"We're very proud of the work surgeons around the country are conducting to fight breast cancer. The Mammo View(TM) has been developed to be a very easy and powerful tool in the fight against breast cancer and providing early detection for women," stated Bob Segerstein, President of Solos Endoscopy, Inc.

About Solos Endoscopy, Inc.:

Solos Endoscopy, Inc. is a healthcare technology company whose mission is to develop and market breakthrough technology, applications, medical devices, and procedural techniques for the screening, diagnosis, treatment and management of medical conditions. Backed by technical support, Solos' sales team can help make the right buying decisions for the hospital, surgery center, or physician office. Additional information is available on the Company's website at: http://www.solosendoscopy.com.

Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.


'/>"/>
SOURCE Solos Endoscopy, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Solos Endoscopy, Inc. in Final Stages to Upgrade Pink Sheet Status from Limited to Current Information
2. Solos Endoscopy, Inc. Implements Strategy to Capitalize on $30 Billion Minimally Invasive Surgical Product Market
3. Sanofi-aventis SoloSTAR(R) Insulin Pen for Lantus and Apidra Receives the Prestigious GOOD DESIGN Award
4. Air Transport Association Applauds House of Representatives on Decision to Withhold Biometric Collection Funding
5. ISMPP Applauds AAMC Clarification on Ghostwriting Versus Transparent Writing Collaboration in Scientific Publications
6. Orchid Cellmark Applauds Expansion of Federal Forensic DNA Identity Testing to Include All Arrestees
7. Childhood Influenza Immunization Coalition Applauds Expanded Influenza Vaccine Recommendation for Children
8. Novo Nordisk Applauds Adoption of World Diabetes Day Resolutions by U.S. Congress
9. FRC Applauds New Ballot Initiative for Cures Without Cloning
10. American Oriental Bioengineering Completes Two Acquisitions
11. CV Therapeutics Announces Presentations at American Heart Association Scientific Sessions 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... ... Parallel 6 , the leading software as a service (SaaS) provider ... Patient Encounter CONSULT module which enables both audio and video telemedicine communication between the ... the CONSULT module, patients and physicians can schedule a face to face virtual patient ...
(Date:6/27/2016)... PHILADELPHIA , June 27, 2016  Liquid ... today announced the funding of a Sponsored Research ... study circulating tumor cells (CTCs) from cancer patients.  ... changes in CTC levels correlate with clinical outcomes ... therapies. These data will then be employed to ...
(Date:6/24/2016)... 24, 2016 Epic Sciences unveiled a ... susceptible to PARP inhibitors by targeting homologous recombination ... The new test has already been incorporated into ... cancer types. Over 230 clinical trials ... pathways, including PARP, ATM, ATR, DNA-PK and WEE-1. ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... the release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” ... and retention in this eBook by providing practical tips, tools, and strategies for ...
Breaking Biology Technology:
(Date:4/28/2016)... Sweden , April 28, 2016 First ... M (139.9), up 966% compared with the first quarter of 2015 ... profit totaled SEK 589.1 M (loss: 18.8) and the operating margin ... 7.12 (loss: 0.32) Cash flow from operations was SEK ... The 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. ...
(Date:4/15/2016)... CHICAGO , April 15, 2016  A ... companies make more accurate underwriting decisions in a ... offering timely, competitively priced and high-value life insurance ... health screenings. With Force Diagnostics, rapid ... and lifestyle data readings (blood pressure, weight, pulse, ...
(Date:3/31/2016)... 2016   LegacyXChange, ... "Company") LegacyXChange is excited to release its ... to be launched online site for trading 100% guaranteed ... will also provide potential shareholders a sense of the ... an industry that is notorious for fraud. The video ...
Breaking Biology News(10 mins):